Volume 6 Supplement 1
15th Paediatric Rheumatology European Society (PreS) Congress
Meeting abstracts
Edited by Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott
15th Paediatric Rheumatology European Society (PreS) Congress. Go to conference site.
London, UK14-17 September 2008
Page 2 of 7
-
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S26
-
MEFV mutations in systemic JIA
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P26 -
13.4 High frequency of CNS involvement in linear scleroderma of the face
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S27 -
Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, double-blind, placebo-controlled trial (ANAJIS)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P27 -
14.1 Clinical spectrum and outcome in 100 children with positive antiphospholipid antibodies
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S28 -
Gene expression in active systemic JIA after anti-IL1 and anti-IL6R treatment
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P28 -
14.2 Causes of early death in juvenile onset systemic lupus erythematosus (JSLE)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S29 -
Early effects of Anakinra in corticosteroid naïve SOJIA patients
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P29 -
14.3 Early cardiovascular risk assessment in patients with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S30 -
Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P30 -
14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S31 -
A phenotypic shift after initiation of IL-1 receptor blockade in a boy with systemic juvenile arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P31 -
14.5 Rheumatoid Arthritis susceptibility loci; STAT4, TRAF1/C5 and 6q23 region, are also associated with Juvenile Idiopathic Arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S32 -
Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret®) in systemic juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P32 -
14.6 MRP-Targeting in experimental rheumatoid arthritis allows monitoring of disease activity with optical molecular imaging
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S33 -
Macrophage activation sydrome with systemic onset juvenile idiopathic arthritis (SOJIA) in Chinese childern
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P33 -
15.3 Agreement between parent and adolescent assessment of disability, pain and well-being: results from the Childhood Arthritis Prospective Study (CAPS)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):S34 -
The TLR4 ligands MRP8 and MRP14 in the diagnosis and pathogenesis of systemic onset juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P34 -
Adverse events during anti-TNF therapy in 269 patients with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P35 -
Anti-tumour necrosis factor (anti-TNF) in the treatment of juvenile idiopathic arthritis-associated uveitis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P36 -
Efficacy and safety of anti-TNF agents in patients with enthesitis related arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P37 -
DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P38 -
Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P39 -
When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P40 -
Switching from a first to a second tumour necrosis factor (TNF) alpha antagonist in patients with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P41 -
Juvenile Psoriatic Arthritis (JPsA) clinical features and outcome of 119 patients
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P42 -
Mandibular condyle destruction in juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P43 -
Efficacy of a second TNF blocker, when the first one failed, in patients with juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P44 -
Relationship between delayed menarche and bone density in patients affected by juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P45 -
Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P46 -
Infliximab to treat chronic uveitis in juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P47 -
Use of Intravenous Immunoglobulin Therapy in a paediatric rheumatology service
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P48 -
A safe protocol for tuberculin test assessment in a country where BCG vaccination is mandatory
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P49 -
Growth retardation in patients with juvenile idiopathic arthritis and growth hormone therapy
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P50 -
Sleep, fatigue and quality of life in juvenile idiopathic arthritis (JIA) and Juvenile Dermatomyositis (JDM)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P51 -
Illness representation in adolescents with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P52 -
Hip arthritis in the TNF-Blockade era: an unresolved issue?
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P53 -
Arthritis in Down's syndrome is still being missed
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P54 -
Evaluation of the power of six clustering features in identifying a homogeneous disease subset in juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P55 -
Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P56 -
HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P57 -
Does unity of Familial Mediterranean fever with juvenile idiopathic arthritis affect the outcome?
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P58 -
Association between inflammatory status and intima-media-thickness in children with juvenile idiopathic arthritis: preliminary data
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P59 -
Performance of IFN-Gamma release assays for detection of tuberculosis infection in juvenile I JIA children in biological therapy
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P60 -
Anti-cyclic citrullinated peptide: its prevalence and clinical significance in a South African cohort with juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P61 -
Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P62 -
Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P63 -
The therapeutic value of low-energy laser (LLLT) for enthesitis in children with juvenile spondyloarthropathies
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P64 -
Methotrexate shows the same efficacy and safety in the real world in all subtypes of JIA as in the controlled trial
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P65 -
Bone mass predictors in a large cohort of children with juvenile idiopathic arthritis (JIA)
Citation: Pediatric Rheumatology 2008 6(Suppl 1):P66
Official journal of
Annual Journal Metrics
-
Citation Impact
3.413 - 2-year Impact Factor (2021)
3.970 - 5-year Impact Factor (2021)
1.315 - Source Normalized Impact per Paper (SNIP)
1.051 - SCImago Journal Rank (SJR)Speed
43 days to first decision for all manuscripts (Median)
53 days to first decision for reviewed manuscripts only (Median)
Usage
917,107 Downloads (2021)
661 Altmetric mentions (2021)